Australia Should Accept U.S. Call For Longer Data Exclusivity On Medicines In TPP
The Hill: Australia should stop stalling negotiations for the Trans-Pacific Partnership
Eric V. Schlecht, writer focused on budget and economic issues in Washington, D.C.
“…The [Trans-Pacific Partnership (TPP)] needs to include robust protections for advanced medicines — or we risk derailing investment in future life-saving medical discoveries. … [R]egulators have established data exclusivity, which prevents outside firms from accessing the research behind a new biopharmaceutical. This prohibition effectively prevents them from violating their intellectual property rights and creating copycat drugs. Here in the United States, data exclusivity is set at 12 years — and for good reason. … If exclusivity were set any shorter, generic firms could flood the market with copies before the original inventor has even gotten out of the red. … Australia is staunchly opposed to setting data exclusivity at 12 years. Its domestic patent system sets it at just five years — the length they want included in the final TPP deal. … Australia should stop resisting America’s calls for robust drug rights and help negotiators finally finish this historic trade deal. Future recipients of these medical innovations deserve no less” (9/18).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.